Hypoadiponectinemia Is an Independent Risk Factor for Hypertension

By Y. Iwashima, T. Katsuya, K. Ishikawa, N. Ouchi, M. Ohishi, K. Sugimoto, Yuxiao Fu, Masaharu Motone, Kouichi Yamamoto, A. Matsuo and 6 more. HYPERTENSION, 2004

616 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/e2b3ca9ea1bad440f6d9cb3f6f2bd9e7764cc819

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

1. H. Fang
2. R. L. Judd
3. Sushil Kumar Jain
4. A. Achari

In Epidemiology

1. H. Fang
2. R. L. Judd
3. Sushil Kumar Jain
4. A. Achari

In Physiology

1. H. Fang
2. R. L. Judd
3. Sushil Kumar Jain
4. A. Achari

Citations in the corpus

• Adiponectin, a Therapeutic Target for Obesity, Diabetes, and Endothelial Dysfunction (2017, background): “Numerous epidemiological studies suggest that adiponectin deficiency (hypoadiponectinemia) is associated with coronary artery disease and hypertension [66], left ventricular hypertrophy [67], and a greater risk of myocardial infarction [68].”
• Adiponectin Regulation and Function (2018, positive): “Clinical and epidemiological studies have correlated low adiponectin concentrations with the development of CAD, myocardial infarction, hypertension, left ventricular hypertrophy, and other cardiovascular dysfunctions (15, 33, 55, 107, 121, 149, 299).”